Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,414 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronary Artery Disease (CAD) Clear all
Completed Phase 2 Interventional Results available

Cangrelor Ticagrelor Transition Study

NCT01766466
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
cangrelor, Ticagrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Determinants of Cardiac Risk Factor Modification in Latinos With Coronary Artery Disease

NCT00248859
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 4 Interventional

Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions

NCT00481741
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Vascular Disease
Interventions
SafeSeal(TM) Hemostasis Patch
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2009 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 13, 2026, 6:08 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

NCT03108456
View directory record Official record
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions
Orbital Atherectomy, Balloon
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 13, 2026, 6:08 PM EDT
Not listed No phase listed Observational

OCT and Scaffold Embedding After NC Balloon

NCT03106961
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bioresorbable vascular scaffolds, OCT, non-compliant ballooning
Device
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional

Effect of Exercise on Elevated C-reactive Protein Concentrations in Formerly Inactive Adults

NCT00113061
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity
Interventions
Exercise
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 13, 2026, 6:08 PM EDT
Not listed Phase 2 Interventional

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

NCT00385385
View directory record Official record
Conditions
Coronary Artery Disease, Cerebrovascular Disease, Peripheral Vascular Disease
Interventions
Rifalazil
Drug
Lead sponsor
ActivBiotics
Industry
Eligibility
50 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Lansing, Michigan • Roslyn, New York • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2007 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women

NCT00000108
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease
Interventions
Exercise
Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
50 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational

RESOLUTE ONYX Post-Approval Study

NCT03063749
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Huntsville, Alabama • La Jolla, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 13, 2026, 6:08 PM EDT
Not listed Not applicable Interventional

Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation

NCT02053038
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iFR, FFR
Device
Lead sponsor
Imperial College London
Other
Eligibility
18 Years to 90 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
6
States / cities
Long Beach, California • Lakewood, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated Phase 2 Interventional

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332
View directory record Official record
Conditions
Arrhythmia
Interventions
GAP-486 (ZP-123), 0.9% Sodium Chloride, USP
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated No phase listed Observational

CorPath GRX STEMI Study

NCT04459299
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction, CAD
Interventions
Robotic-PCI (CorPath GRX System)
Device
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining the Long-Term Risks of Oophorectomy

NCT00655447
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Breast Cancer, Ovarian Cancer, Cancer, Hip Fracture, Death
Interventions
Not listed
Lead sponsor
Parker, William H., M.D.
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
32,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1980 – 2004
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Oct 13, 2026, 6:08 PM EDT
Not listed No phase listed Observational

Multidisciplinary Approach to Reduce Cardiovascular Health Disparities

NCT06168968
View directory record Official record
Conditions
Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease, Ischemic Stroke
Interventions
Life and Medication Recommendations
Behavioral
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 13, 2026, 6:08 PM EDT
Not listed Phase 4 Interventional

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

NCT02012140
View directory record Official record
Conditions
Cardiovascular Disease, Stable Angina, Myocardial Infarction, Coronary Artery Disease
Interventions
ticagrelor
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET

NCT00733460
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BFPET
Drug
Lead sponsor
Fluoropharma, Inc.
Industry
Eligibility
20 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 13, 2026, 6:08 PM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 4 Interventional

18F-fluoride (18F-NaF) PET for Identifying Coronary Atherosclerotic Plaques

NCT02607748
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerotic Plaque
Interventions
18F-NaF PET and coronary CTA imaging
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Expression of Longevity Genes in Response to Extended Fasting

NCT01059760
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Fasting First, Fed First
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 3 Interventional

Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions

NCT00371423
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté™-SR
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Little Rock, Arkansas • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 13, 2026, 6:08 PM EDT
Terminated Phase 4 Interventional Results available

Risk Factor Control Before Orthopedic Surgery

NCT01837069
View directory record Official record
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 13, 2026, 6:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

NCT01094275
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel 75mg, Omeprazole 20mg
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 13, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

NCT00543400
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
M118, Unfractionated Heparin
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
19 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
37
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 13, 2026, 6:08 PM EDT